Press Releases
AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results
February 17, 2026
Fourth Quarter 2025 worldwide revenue of $140.5 million – an increase of 13.1% year over year Fourth Quarter 2025 net income of $1.8 million and positive adjusted EBITDA of $19.9 million Full Year 2025 worldwide revenue of $534.5 million – an increase of 14.9% year over year Full Year 2025 net loss...
AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results
January 27, 2026
MASON, Ohio --(BUSINESS WIRE)--Jan. 27, 2026-- AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter...
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026
January 12, 2026
MASON, Ohio --(BUSINESS WIRE)--Jan. 12, 2026-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for...
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference
December 17, 2025
MASON, Ohio --(BUSINESS WIRE)--Dec. 17, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure Announces the First Patients Treated with Novel Dual Energy Platform
December 11, 2025
New technology combines Pulsed Field Ablation (PFA) and Advanced Radiofrequency Ablation with AtriCure’s EnCompass ® clamp to reduce treatment time for surgical ablation patients MASON, Ohio --(BUSINESS WIRE)--Dec. 11, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical...
AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 18, 2025
MASON, Ohio --(BUSINESS WIRE)--Nov. 18, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025
October 29, 2025
Worldwide revenue of $134.3 million – an increase of 15.8% year over year (15.1% constant currency) Net loss of $0.3 million – an improvement of $7.6 million year over year Adjusted EBITDA of $17.8 million – an increase of $9.9 million year over year Generated $30.1 million of cash in the third...
AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial
October 28, 2025
Trial will evaluate the safety and effectiveness of the AtriCure Isolator ® Synergy™ EnCompass ® clamp and AtriClip ® Left Atrial Appendage Exclusion System to reduce the occurrence of new-onset atrial fibrillation in cardiac surgery patients MASON, Ohio --(BUSINESS WIRE)--Oct....
AtriCure to Participate in Upcoming Investor Conferences
October 27, 2025
MASON, Ohio --(BUSINESS WIRE)--Oct. 27, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure to Announce Third Quarter 2025 Financial Results
October 08, 2025
MASON, Ohio --(BUSINESS WIRE)--Oct. 8, 2025-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter...